Clearmind Medicine, a Vancouver-based psychedelic drugs company, has entered a patent licensing agreement with Yissum Research Development Company at the Hebrew University of Jerusalem. The collaboration focuses on developing and utilizing psychedelic compounds to treat post-traumatic stress disorder (PTSD) and other mental health illnesses.
Under the terms of the agreement, Clearmind gains exclusive global rights to develop, manufacture, and commercialize novel compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel from the Hebrew University. Clearmind assumes responsibility for further development and potential commercialization while adhering to regulations. Terms of the agreement also include future milestone payments, royalties on sales, and commitments to safeguard patents.
Analyst QuickTake: This partnership follows a prior collaboration with Yissum in April 2024 aimed at developing psychedelic compounds for addiction and mental health disorders.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.